XML 76 R65.htm IDEA: XBRL DOCUMENT
v3.19.3

Business Combinations - Narrative (Details) $ / shares in Units, $ in Millions |  |  |  |  |  |  | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 01, 2019 USD ($) | Oct. 01, 2018 USD ($) | Jul. 31, 2018 USD ($) | Dec. 11, 2017 USD ($) | Apr. 07, 2017 USD ($) | Mar. 22, 2017 USD ($) project $ / shares | Sep. 28, 2019 USD ($) | Mar. 30, 2019 USD ($) | Mar. 31, 2018 USD ($) | Sep. 30, 2017 USD ($) | Sep. 30, 2017 USD ($) | Sep. 28, 2019 USD ($) | Sep. 29, 2018 USD ($) | Sep. 30, 2017 USD ($)
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  |  |  |  |  |  | $ 2,563.7 |  |  |  |  | $ 2,563.7 | $ 2,533.2 |
Goodwill impairment |  |  |  |  |  |  |  |  | $ 685.7 |  |  | 0.0 | 685.7 | $ 0.0
Payment of contingent holdbacks |  |  |  |  |  |  |  |  |  |  |  | 6.5 | 0.0 | $ 0.0
Cynosure |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase price (in dollars per share) | $ / shares |  |  |  |  |  | $ 66.00 |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  | $ 1,660.0 |  |  |  |  |  |  |  |
Direct transaction costs |  |  |  |  |  | 18.8 |  |  |  |  |  |  |  |
Goodwill |  |  |  |  |  | $ 685.7 |  |  |  |  |  |  |  |
Goodwill impairment |  |  |  |  |  |  |  |  | 685.7 |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  |  | $ 207.5 |  |  |
Pre-tax loss |  |  |  |  |  |  |  |  |  |  | $ 96.4 |  |  |
Cynosure | Other intangible assets | Measurement Input, Discount Rate | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value discount rate (percent) |  |  |  |  |  | 11.00% |  |  |  |  |  |  |  |
Cynosure | Other intangible assets | Measurement Input, Discount Rate | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value discount rate (percent) |  |  |  |  |  | 12.00% |  |  |  |  |  |  |  |
Cynosure | In-process research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets |  |  |  |  |  | $ 107.0 |  |  |  |  |  |  |  |
Number of projects related to IPR&D acquired | project |  |  |  |  |  | 3 |  |  |  |  |  |  |  |
Estimated costs to complete |  |  |  |  |  | $ 18.0 |  |  |  |  |  |  |  |
Cynosure | In-process research and development | Measurement Input, Discount Rate | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value discount rate (percent) |  |  |  |  |  | 14.00% |  |  |  |  |  |  |  |
Cynosure | In-process research and development | Measurement Input, Discount Rate | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value discount rate (percent) |  |  |  |  |  | 22.00% |  |  |  |  |  |  |  |
Cynosure | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairment charges |  |  |  |  |  |  | 238.6 | $ 685.4 |  |  |  |  |  |
Project fair value |  |  |  |  |  |  |  |  |  | $ 61.0 |  |  |  |
Impairment charge |  |  |  |  |  |  |  |  | $ 46.0 |  |  |  |  |
Weighted average amortization period |  |  |  |  |  | 11 years 9 months 18 days |  |  |  |  |  |  |  |
Cynosure | Distribution agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period |  |  |  |  |  | 8 years |  |  |  |  |  |  |  |
Cynosure | Customer relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period |  |  |  |  |  | 7 years 8 months 12 days |  |  |  |  |  |  |  |
Cynosure | Trade names |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period |  |  |  |  |  | 8 years 10 months 24 days |  |  |  |  |  |  |  |
Medicor Medical Supply |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  | $ 19.0 |  |  |  |  |  |  |  |  |
Intangible assets |  |  |  |  | 5.4 |  |  |  |  |  |  |  |  |
Goodwill |  |  |  |  | 8.9 |  |  |  |  |  |  |  |  |
Tangible assets and liabilities, net |  |  |  |  | $ 4.7 |  |  |  |  |  |  |  |  |
Weighted average amortization period |  |  |  |  | 7 years 8 months 12 days |  |  |  |  |  |  |  |  |
Acquisition price working capital adjustment |  |  |  |  | $ 2.0 |  |  |  |  |  |  |  |  |
Medicor Medical Supply | Holdback |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  |  |  | $ 1.9 |  |  |  |  |  |  |  |  |
Payment period for contingent consideration |  |  |  |  | 2 years |  |  |  |  |  |  |  |  |
Emsor |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  | $ 16.3 |  |  |  |  |  |  |  |  |  |
Intangible assets |  |  |  | 4.6 |  |  |  |  |  |  |  |  |  |
Goodwill |  |  |  | 5.7 |  |  |  |  |  |  |  |  |  |
Tangible assets and liabilities, net |  |  |  | 6.0 |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  |  | 4.9 |  |  |  |  |  |  |  |  |  |
Emsor | Holdback |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  |  | $ 0.5 |  |  |  |  |  |  |  |  |  |
Payment period for contingent consideration |  |  |  | 18 months |  |  |  |  |  |  |  |  |  |
Faxitron |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  | $ 89.5 |  |  |  |  |  |  |  |  |  |  |
Intangible assets |  |  |  |  |  |  |  |  |  |  |  |  | $ 53.4 |
Goodwill |  |  | 45.6 |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  | 2.9 |  |  |  |  |  |  |  |  |  |  |
Increase in contingent consideration liability |  |  |  |  |  |  | $ 1.7 |  |  |  |  |  |  |
Faxitron | Holdback |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  | $ 11.7 |  |  |  |  |  |  |  |  |  |  |
Payment period for contingent consideration |  |  | 1 year |  |  |  |  |  |  |  |  |  |  |
Payment of contingent holdbacks |  |  |  |  |  |  |  |  |  |  |  | 6.5 |  |
Contingent holdback withheld under indemnification provisions |  |  |  |  |  |  |  |  |  |  |  | $ 5.2 |  |
Faxitron | In-process research and development | Measurement Input, Discount Rate | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value discount rate (percent) |  |  | 17.00% |  |  |  |  |  |  |  |  |  |  |
Faxitron | In-process research and development | Measurement Input, Discount Rate | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value discount rate (percent) |  |  | 19.00% |  |  |  |  |  |  |  |  |  |  |
Faxitron | Customer relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period |  |  | 9 years |  |  |  |  |  |  |  |  |  |  |
Faxitron | Trade names |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period |  |  | 7 years |  |  |  |  |  |  |  |  |  |  |
Focal Therapeutics |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  | $ 120.1 |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  | 31.1 |  |  |  |  |  |  |  |  |  |  |  |
Focal Therapeutics | Holdback |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  | 14.0 |  |  |  |  |  |  |  |  |  |  |  |
Payment of contingent consideration |  |  |  |  |  |  |  | $ 1.5 |  |  |  |  |  |
Focal Therapeutics | Holdback | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment of contingent consideration | $ 12.5 |  |  |  |  |  |  |  |  |  |  |  |  |
Focal Therapeutics | In-process research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets |  | $ 11.4 |  |  |  |  |  |  |  |  |  |  |  |
Focal Therapeutics | In-process research and development | Measurement Input, Discount Rate | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value discount rate (percent) |  | 15.50% |  |  |  |  |  |  |  |  |  |  |  |
Focal Therapeutics | In-process research and development | Measurement Input, Discount Rate | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value discount rate (percent) |  | 16.50% |  |  |  |  |  |  |  |  |  |  |  |
Focal Therapeutics | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets |  | $ 83.1 |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period |  | 11 years |  |  |  |  |  |  |  |  |  |  |  |
Focal Therapeutics | Trade names |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets |  | $ 2.7 |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period |  | 13 years |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Payment for working capital adjustment + References No definition available. + Details
Name: | holx_AcquisitionPriceAdjustment
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business Combination, Contingent Consideration, Withheld Under Indemnification Provisions + References No definition available. + Details
Name: | holx_BusinessCombinationContingentConsiderationWithheldUnderIndemnificationProvisions
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Business Combination, Period for Payment of Contingent Consideration Liability + References No definition available. + Details
Name: | holx_BusinessCombinationPeriodforPaymentofContingentConsiderationLiability
Namespace Prefix: | holx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value + References No definition available. + Details
Name: | holx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedIntangibleAssetsFairValue
Namespace Prefix: | holx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets And Liabilities, Net + References No definition available. + Details
Name: | holx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssetsAndLiabilitiesNet
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number Of Projects + References No definition available. + Details
Name: | holx_NumberOfProjects
Namespace Prefix: | holx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the cash payment of contingent consideration to the former shareholders of the acquired company. + References No definition available. + Details
Name: | holx_PaymentOfContingentConsideration
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Project Fair Value + References No definition available. + Details
Name: | holx_ProjectFairValue
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research and Development Assets Acquired, Expected Remaining Cost to Complete + References No definition available. + Details
Name: | holx_ResearchandDevelopmentAssetsAcquiredExpectedRemainingCosttoComplete
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of intangible assets, excluding goodwill, acquired at the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266 + Details
Name: | us-gaap_Goodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266 + Details
Name: | us-gaap_GoodwillImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585 + Details
Name: | us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_CynosureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=holx_DistributionagreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_MedicorMedicalSupplyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=holx_ContingentHoldbackMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_EmsorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_FaxitronMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_FocalTherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |